Ibrutinib in chronic lymphocytic leukemia and B cell malignancies

Abstract

Recent clinical data suggest remarkable activity of ibrutinib, the first-in-class covalent inhibitor of Bruton's tyrosine kinase (BTK), in chronic lymphocytic leukemia (CLL), as well as excellent activity in other B cell malignancies, including in particular mantle cell lymphoma and Waldenstrom macroglobulinemia. This review evaluates the data from ongoing clinical and correlative studies of ibrutinib in B cell malignancies with a particular focus on CLL, and considers these data in the context of other B cell receptor pathway inhibitors.

Keywords::

• Ibrutinib
• BTK
• CLL
• NHL

Potential conflict of interest:

A disclosure form provided by the author is available with the full text of this article at www.informahealthcare.com/lal.

J. R. B. is a Scholar in Clinical Research of the Leukemia and Lymphoma Society and is supported by grants from the Leukemia and Lymphoma Society and the American Cancer Society.